Retatrutide (LY3437943), an Eli Lilly triple agonist hitting the GLP-1, GIP and glucagon receptors, has become one of the most talked-about compounds in weight-loss and bodybuilding circles on Reddit, X and TikTok. The interest is grounded in real data: a phase-2 trial published in the New England Journal of Medicine in 2023 (Jastreboff et al., 338 participants) reported least-squares mean body-weight reductions of -17.1% at the 4-mg dose, -22.8% at 8 mg and -24.2% at 12 mg over 48 weeks, versus -2.1% for placebo. That is the largest mean weight loss reported for any incretin-based drug to date, which is why it has been branded the strongest GLP-1 yet.
The catch is that retatrutide is still investigational. As of 2026 it remains in phase-3 trials (the TRIUMPH programme) and is not approved for any indication anywhere. The only sanctioned way to receive it is inside a clinical trial. That gap between hype and access is what has driven demand to the grey market, where 'research-grade' peptide vials are sold online, often labelled not for human consumption.
Regulators have moved against this. The FDA issued warning letters to companies selling compounded retatrutide, stating the compound cannot be legally compounded under either section 503A or 503B of the Food, Drug and Cosmetic Act — it has no USP/NF monograph, is not a component of any approved drug, and appears on neither bulks list. The agency framed the products as unapproved new drugs, misbranded for lacking adequate directions for safe use.
The honest evidence picture: efficacy signals are strong for a drug at this stage, but there is no long-term safety data, no cardiovascular outcome data, and grey-market vials carry unverified purity, dosing and sterility. Dose-related gastrointestinal adverse events were the most common in-trial, and heart-rate increases have been noted with the class. Anything sourced outside a trial is unstudied at that specific concentration and purity.